Shanghai Haihe Biopharma Co., Ltd. announced that it has entered into an financing agreement and received $146.6 million in its series B round of funding led by HG Healthcare Venture Capital Chengdu Partnership Enterprise (Limited Partnership), a fund managed by Beijing HuaGai Healthcare Investment Management Co., Ltd. on February 11, 2019. The transaction also included participation from CSPC Pharmaceutical Group Limited (SEHK:1093), DAE HWA Pharmaceutical Co., Ltd. (KOSDAQ:A067080), Hillhouse Capital Management, Ltd., Boyuan Capital Limited, Atlas Capital, Yingke Innovation Asset Management Co., Ltd., Elite Capital, CAS Venture Capital Management Co., Ltd.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10,210 KRW | +1.39% | -6.24% | +8.85% |
1st Jan change | Capi. | |
---|---|---|
+8.85% | 131M | |
+15.09% | 74.45B | |
+11.05% | 9.18B | |
+54.35% | 5.03B | |
-12.85% | 5.02B | |
+1.60% | 3.82B | |
-20.85% | 2.41B | |
+16.88% | 2.39B | |
-29.25% | 2.27B | |
+24.62% | 2.26B |
- Stock Market
- Equities
- A067080 Stock
- News DAE HWA Pharmaceutical Co., Ltd.
- Shanghai Haihe Biopharma Co., Ltd. announced that it has received $146.6 million in funding from a group of investors